NCT06961357 2025-12-03
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT05893654 2025-09-15
MELCOM
Hospital das ClÃnicas de Ribeirão Preto
Phase 1/2 Enrolling by invitation
NCT04283890 2025-09-09
CHOPIN
Leiden University Medical Center
Phase 1/2 Active not recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting
NCT04364230 2024-07-16
Mel66
University of Virginia
Phase 1/2 Completed
NCT04589832 2023-11-22
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT05677373 2023-08-18
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT05047276 2021-09-17
PULSE-UM
Institut d'Investigació Biomèdica de Bellvitge
Phase 1/2 Unknown
NCT02913417 2021-04-19
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
California Pacific Medical Center Research Institute
Phase 1/2 Unknown
NCT00929019 2018-12-07
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Radboud University Medical Center
Phase 1/2 Terminated
NCT02654821 2018-11-02
TCR
The Netherlands Cancer Institute
Phase 1/2 Unknown
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00005815 2013-06-19
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed